Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Kenvue (KUVE) has named Kirk Perry, a current director, as its interim CEO, effective immediately. Concurrently, Thibaut ...

For FY24, Kenvue reaffirms its outlook for net sales growth of 1% to 3% and adjusted earnings of $1.10 to $1.20 per share versus Street estimates for $1.14 in earnings on $15.65B in revenue.

Kenvue says that CEO Thibaut Mongon is departing as the maker of Listerine and Band-Aid brands continues with a strategic ...

Johnson & Johnson's former consumer unit, Kenvue Inc KVUE, reported its first quarterly earnings after being spun off in May.. Q2 sales increased 5.4% Y/Y to $4.01 billion, a Y/Y increase of 5.4% ...

Despite the earnings beat, Kenvue (NYSE:KVUE)’s stock dipped 0.9% following the release, suggesting a muted market reaction to the results. For the full year 2025, Kenvue now expects net sales ...

Kenvue Inc. (NYSE:KVUE) Q2 2023 Earnings Conference Call July 20, 2023 7:30 AM ETCompany ParticipantsTina Romani - Head, Investor RelationsThibaut Mongon - ...

Kenvue KVUE reported third-quarter earnings that were in line with our expectations. Total sales were up 3.3% year over year, largely thanks to price and mix, which contributed to 7.1% of total ...

Q1 revenue hit $3.74 billion vs. $3.68 billion consensus; sales down 3.9% YoY on lower volume and currency impact. Adjusted operating margin fell to 19.8% from 22.0% YoY 3 Summer "Power Patterns ...

Kenvue (KVUE) delivered earnings and revenue surprises of 14.29% and 1.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Kenvue (KVUE) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.32 per share a year ago. These figures ...